Tempus AI, Inc. - Class A Common Stock (TEM)

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:BTAI),(OTCPK:HWAIF),(OTCQX:WHTCF) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company’s use of AI-driven solutions to advance precision oncology.

Shares of Tempus AI, Inc. fell over 19% in intraday trading on Wednesday, May 28, 2025, after Spruce Point Capital Management published a report alleging that Tempus AI is engaging in “aggressive and suspicious accounting practices,” and the company’s leaders are “connected to troubling financial restatements and SEC-charged fraud allegations.” Gibbs Mura is investigating a potential Tempus AI, Inc. (NASDAQ: TEM) Securities Class Action Lawsuit on behalf of shareholders who lost money in Tempus AI, Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) for violations of the securities laws.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus’ ongoing commitment to accelerating scientific discovery and delivering data-driven insights that improve patient outcomes.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL.

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study reveals the potentially transformative impact of Ambry Genetics’ Patient for Life™ program, which systematically reanalyzes data from the company’s database of exome test results. By reclassifying genetic variants based on newly discovered gene-disease associations and emerging evidence supporting variant pathogenicity, the program may offer renewed hope to patients and families facing undiagnosed rare diseases. Over the study period, 5% of initially negative or uninformative case results that received proactive reanalysis led to a diagnosis.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC) and was the basis of the recent U.S. Food and Drug Administration’s (FDA) accelerated approval of the combination in KRAS-mutated recurrent LGSOC.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data on health economics and outcomes research.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients’ electronic health records.

PALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast amounts of medical data, including patient records and genetic information. This efficiency allows healthcare professionals to diagnose conditions more quickly and accurately, leading to better patient outcomes. AI-powered diagnostic tools can detect subtle patterns and indicators of diseases; this offers early detection and further works on early prevention of diseases. AI systems also help in assisting healthcare professionals with valuable tools, all these factors that offer improved diagnosis process act as a driver for the market’s growth. A report from MarketsAndMarkets projected that the global AI in medical diagnostics market is forecasted to grow at a robust CAGR of 22.5%, reaching US$1.71 billion in 2024 and an impressive US$4.72 billion by 2029. The report said: “Government initiatives towards increasing Al-based technologies, access to finance for Al-based startups, big data influx, and growing cross-industry alliances and collaborations are key drivers of this market's growth. Growth in the AI in medical diagnostics market is primarily driven by the growing demand for AI tools, increasing focus on reducing the workload of radiologists, influx of large & complex datasets, funding for AI based startups, and growing cross-industry partnerships & collaborations.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), Teladoc Health, Inc. (NYSE: TDOC), GE HealthCare (NASDAQ: GEHC).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression.

PALM BEACH, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in Diabetic Retinopathy Market is witnessing unprecedented growth, reshaping the landscape of diagnostic and therapeutic interventions for this prevalent and sight-threatening complication of diabetes. As technology continues to advance, artificial intelligence (AI) is emerging as a transformative force in healthcare, particularly in the domain of diabetic retinopathy (DR), where early detection and timely intervention are critical. The report said “AI applications in diabetic retinopathy are gaining momentum due to their ability to augment traditional diagnostic methods. Image analysis, a cornerstone in the detection of retinal abnormalities, has witnessed a paradigm shift with the incorporation of AI algorithms. These algorithms, trained on vast datasets of retinal images, demonstrate remarkable accuracy in identifying subtle changes indicative of diabetic retinopathy. Consequently, they empower healthcare professionals with more efficient and precise tools for early diagnosis. One of the notable contributions of AI in diabetic retinopathy lies in its potential to address the challenge of limited access to ophthalmic expertise, especially in resource-constrained regions. Automated screening processes, driven by AI, enable remote and quick assessment of retinal images, offering a scalable solution to bridge the gap in healthcare accessibility. This democratization of expertise has the potential to revolutionize the way diabetic retinopathy is diagnosed and managed globally.” According to a report issued by Grand View Research: “the global diabetic retinopathy market size was estimated at USD $9.48 Billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion.”   Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Recursion (NASDAQ: RXRX), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), ADMA Biologics, Inc. (NASDAQ: ADMA).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus’ proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes.

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.